Anti-progestin therapy targets hallmarks of breast cancer risk.

ABSTRACT: Breast cancer is the leading cause of cancer-related death in women worldwide¹. Here, in the Breast Cancer-Anti-Progestin Prevention Study 1 (BC-APPS1; NCT02408770 ), we assessed whether progesterone receptor antagonism with ulipristal acetate for 12 weeks reduces surrogate markers of breast cancer risk in 24 premenopausal women. We used multilayered OMICs and live-cell approaches as readouts for molecular features alongside clinical imaging and tissue micromechanics correlates. Ulipristal acetate reduced epithelial proliferation (Ki67) and the proportion, proliferation and colony formation capacity of luminal progenitor cells, the putative cell of origin of aggressive breast cancers². MRI scans showed reduction in fibroglandular volume with treatment, whereas single-

SUBMITTER: Simoes BM 

PROVIDER: S-EPMC12711567 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature